ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Nemus Bioscience has picked the controlled-substance manufacturing specialist Noramco to scale up production of cannabidiol-valine-hemisuccinate, a cannabidiol analog Nemus licensed from the University of Mississippi. The biotech firm says the analog is more bioavailable than cannabidiol as a treatment for ocular diseases. Meanwhile, Nemus hopes this year to begin clinical trials of a related product, tetrahydrocannabinol-valine-hemisuccinate, licensed from UM and produced by Albany Molecular Research for treating glaucoma.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter